UroGen Pharma
CompanyUnited States
UroGen Pharma develops 2 assets, the furthest approved (mitomycin c in Glaucoma Surgery). Mostly small molecule acting on apoptosis and DNA damage response; based in the United States.
- 2
- Assets
- Furthest stage
- Approved
- Raised
- US$120m
- 9
- Trials
- 5
- Signals
Pipeline
2Cross-links DNA, inhibiting DNA synthesis and causing cancer cell death.
Approved, Small molecule, Apoptosis, Glaucoma Surgery, Non-Muscle Invasive Bladder Cancer
Hydrogel-based formulation of mitomycin delivering localized chemotherapy
Approved, Small molecule, DNA damage response, low-grade upper tract urothelial cancer
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials9
- Funding rounds and grants1
- Deals8
- Signals20
- Similar companies6